vorapaxar   Click here for help

GtoPdb Ligand ID: 4047

Synonyms: SCH 530348 | SCH-530348 | SCH530348 | Zontivity®
Approved drug PDB Ligand
vorapaxar is an approved drug (FDA (2014))
Compound class: Synthetic organic
Comment: Vorapaxar is an orally active thrombin receptor (PAR1) antagonist based on the natural product himbacine [1], that is used as an anti-thrombosis drug.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: vorapaxar

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 77.52
Molecular weight 492.24
XLogP 5.52
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCOC(=O)NC1CCC2C(C1)CC1C(C2C=Cc2ccc(cn2)c2cccc(c2)F)C(OC1=O)C
Isomeric SMILES CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C
InChI InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1
InChI Key ZBGXUVOIWDMMJE-QHNZEKIYSA-N
No information available.
Summary of Clinical Use Click here for help
Approved to reduce the risk of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).
SARS-CoV-2 and COVID-19: Antagonism of PAR1 and the resulting anti-thrombotic action may be applicable to the management of pathological thrombosis and endotheliitis in patients with severe COVID-19 [2].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Vorapaxar is an antagonist of the protease-activated receptor-1 (PAR1) expressed on platelets. The effect is to inhibit thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. Drug action reduces the formation of blood clots and reduces the risk of cardiovascular events and stroke. Due to its long receptor dissociation half-life of (~20 hours) it acts effectively in an irreversible fashion. Its very long elimination half-life, means it is long-acting, displaying significant inhibition of platelet aggregation for up to 4 weeks after discontinuation [3].
External links Click here for help
For extended ADME data see the following:

Drugs.com